|
Kamada Ltd is a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics using its proprietary chromatographic purification technology.
Highlights
1991 - Kamada was founded in Israel and by 1998, was manufacturing 10 products in 15 countries.
2004 - Kamada received Orphan Drug Designation for inhaled AAT(Alpha-1 Antitrypsin) by the FDA and EMEA. AAT became Kamada's flagship product for the treatment of various lung disorders.
2005 - Kamada became Israel's first public biopharmaceutical company.
2006 - A strategic agreement was reached with Germany's PARI Pharma to develop inhalation of AAT.
2007 - Kamada was granted a US patent for Transferrin.
2007 - Intravenous AAT Phase III clinical trials began in the US ; EMEA approved
inhaled AAT Phase-II-III clinical plans and FDA approval was granted for KamRab,
an anti-rabies immune drug Phase II-III clinical plans.
2008 - Kamada received a European patent for its AAT Manufacturing Process.
2008 - Kamada and PARI have entered a new licensing agreement to use PARIs eFlow electronic drug nebulizer with additional indications for Kamada's AAT drug.
2008 - Aerosolized AAT is currently undergoing Phase II clinical trials for the treatment of Cystic Fibrosis and Bronchiectasis.
Returns and Investments
2008-Kamada entered into a $ 4 Million private equity investment agreement with Shavit Capital Fund.
2008-Kamada signed a $20M financing agreement with US based Hercules Technology Growth Capital, Inc.
2008-Total revenues for 2007 were $13.5 million (S&P)
|